ALX Oncology Holdings Inc Ordinary Shares ALXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
-
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
-
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
-
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
-
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
-
ALX Oncology shares jump 9% after Jefferies upgrade
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.64–1.74
- 52-Week Range
- $1.64–17.83
- Bid/Ask
- $1.60 / $1.71
- Market Cap
- $88.49 Mil
- Volume/Avg
- 371,570 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 81
- Website
- https://www.alxoncology.com
Comparables
Valuation
|
Metric
|
ALXO
|
NUVL
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.57 | 10.52 | 0.57 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ALXO
NUVL
PRLD
Financial Strength
|
Metric
|
ALXO
|
NUVL
|
PRLD
|
|---|---|---|---|
Quick Ratio | 4.24 | 17.23 | 7.71 |
Current Ratio | 4.39 | 17.44 | 7.83 |
Interest Coverage | −108.69 | — | — |
Quick Ratio
ALXO
NUVL
PRLD
Profitability
|
Metric
|
ALXO
|
NUVL
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −63.04% | −23.36% | −40.98% |
Return on Equity (Normalized) | −80.04% | −24.62% | −46.70% |
Return on Invested Capital (Normalized) | −80.18% | −28.80% | −44.57% |
Return on Assets
ALXO
NUVL
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Npzghpvgr | Wjsn | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jybldnwrk | Yqnrp | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mdhcvxl | Nrkrt | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Znjyccz | Rhcdvb | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Tcpnfdz | Qtqt | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Yfpkcrhh | Xdpv | $28.5 Bil | |||
| Moderna Inc
MRNA
| Jpvgnygf | Kctf | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Wdbbxcgg | Xrcdk | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ywhjtgrm | Vccqrpr | $13.0 Bil | |||
| Incyte Corp
INCY
| Txtcjqkv | Ydkzrzh | $12.9 Bil |
United States